Mabpharm Ltd
02181
Company Profile
Business description
Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab). Company operates in Chinese Mainland and Others.
Contact
Lujia Road East, Koutai Road West
Block G79, China Medical City
Taizhou225300
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
383
Stocks News & Analysis
stocks
Nvidia earnings: Another stellar quarter with no signs of a slowdown
Nvidia remains at the heart of the AI ecosystem.
stocks
Chart of the Week: Software selloff creates opportunity for these two stocks
Can AI disrupt the software business model?
stocks
Market is misinterpreting AI impact on cheap ASX share
Unwarranted sell-off with shares down by half in three months.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,411.60 | 24.50 | -0.26% |
| CAC 40 | 8,559.07 | 39.86 | 0.47% |
| DAX 40 | 25,175.94 | 189.69 | 0.76% |
| Dow JONES (US) | 49,482.15 | 307.65 | 0.63% |
| FTSE 100 | 10,806.41 | 125.82 | 1.18% |
| HKSE | 26,645.98 | 119.74 | -0.45% |
| NASDAQ | 23,152.08 | 288.39 | 1.26% |
| Nikkei 225 | 58,759.47 | 176.35 | 0.30% |
| NZX 50 Index | 13,634.75 | 109.17 | 0.81% |
| S&P 500 | 6,946.13 | 56.06 | 0.81% |
| S&P/ASX 200 | 9,179.60 | 23.30 | -0.25% |
| SSE Composite Index | 4,144.08 | 3.15 | -0.08% |